CLOVIS ONCOLOGY INC has a total of 28 patent applications. It increased the IP activity by 100.0%. Its first patent ever was published in 2012. It filed its patents most often in WIPO (World Intellectual Property Organization), United States and EPO (European Patent Office). Its main competitors in its focus markets pharmaceuticals, organic fine chemistry and measurement are SIERRA ONCOLOGY INC, MARSHALL BARRY JAMES and T3D THERAPEUTICS INC.
# | Country | Total Patents | |
---|---|---|---|
#1 | WIPO (World Intellectual Property Organization) | 6 | |
#2 | United States | 5 | |
#3 | EPO (European Patent Office) | 4 | |
#4 | Australia | 2 | |
#5 | China | 2 | |
#6 | Brazil | 1 | |
#7 | Canada | 1 | |
#8 | Hong Kong | 1 | |
#9 | Israel | 1 | |
#10 | Japan | 1 | |
#11 | Republic of Korea | 1 | |
#12 | Mexico | 1 | |
#13 | Russian Federation | 1 | |
#14 | Singapore | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Organic fine chemistry | |
#3 | Measurement | |
#4 | Biotechnology |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Therapeutic chemical compounds | |
#3 | Heterocyclic compounds | |
#4 | Analysing materials | |
#5 | Measuring microorganism processes |
# | Name | Total Patents |
---|---|---|
#1 | Etter Jeffrey | 11 |
#2 | Lai Mei | 5 |
#3 | Lin Kevin | 4 |
#4 | Allen Andrew Roger | 4 |
#5 | Harding Thomas Christian | 3 |
#6 | Jeffrey Etter | 3 |
#7 | Simmmons Andrew D | 2 |
#8 | Etter Dzheffri | 1 |
#9 | Isaacson Jeffrey Dean | 1 |
#10 | Simmons Andrew D | 1 |
Publication | Filing date | Title |
---|---|---|
WO2016164217A1 | Therapeutic combinations for treating cancer | |
WO2016029002A2 | Growth factor receptor inhibitors | |
WO2016028689A1 | High dosage strength tablets of rucaparib | |
WO2015112705A2 | Therapeutic combinations for treating cancer | |
CN105917007A | Use of PARP inhibitors to treat breast or ovarian cancer patients showing a loss of heterozygosity | |
WO2014182593A1 | Salts of an epidermal growth factor receptor kinase inhibitor | |
EP2739290A2 | Method for selection of chemotherapeutic agents for adenocarcinoma cancer |